OBJECTIVE: Extracellular matrix metalloproteinase inducer (EMMPRIN) is a glycosylated member of the immunoglobulin superfamily whose function in human seminomas is unknown. We have recently determined that EMMPRIN possesses the ability to stimulate fibroblast and endothelial cell matrix metalloproteinase production, and that its expression was frequently up-regulated in several tumours of the urinary system. Thus, EMMPRIN expression might be associated with the progression of human seminomas. The aim of this study was to investigate whether the presence of EMMPRIN in seminoma tissues might help to predict the patients' prognosis. METHODS: Paraffin-embedded tissues from 65 patients with seminomas and 20 normal testes were processed for immunohistochemical staining using a mouse monoclonal antibody generated against human EMMPRIN, as primary antibody, and a biotinylated goat-anti-mouse IgG, as secondary antibody. In addition, the correlation of EMMPRIN expression with clinicopathologic characteristics and patients' prognosis was also analysed. RESULTS: EMMPRIN was detected in cancerous tissues of 53 patients with seminoma, but not normal testes. Thirty- five patients showed weakly to moderately positive and 18 patients intensely positive expression. Moreover, positive EMMPRIN staining correlated significantly with various clinicopathological factors (increased TNM stage and higher histological differentiation type) as well as decreased tumour-specific survival (log-rank, p=0.02). In particular, EMMPRIN expression was an independent prognosticator as shown by Cox regression analysis (p<0.001). CONCLUSION: EMMPRIN expression in a primary tumour predicts an unfavourable prognosis in human seminoma, suggesting its crucial role in the progression of this tumour.
OBJECTIVE:Extracellular matrix metalloproteinase inducer (EMMPRIN) is a glycosylated member of the immunoglobulin superfamily whose function in humanseminomas is unknown. We have recently determined that EMMPRIN possesses the ability to stimulate fibroblast and endothelial cell matrix metalloproteinase production, and that its expression was frequently up-regulated in several tumours of the urinary system. Thus, EMMPRIN expression might be associated with the progression of humanseminomas. The aim of this study was to investigate whether the presence of EMMPRIN in seminoma tissues might help to predict the patients' prognosis. METHODS:Paraffin-embedded tissues from 65 patients with seminomas and 20 normal testes were processed for immunohistochemical staining using a mouse monoclonal antibody generated against humanEMMPRIN, as primary antibody, and a biotinylated goat-anti-mouse IgG, as secondary antibody. In addition, the correlation of EMMPRIN expression with clinicopathologic characteristics and patients' prognosis was also analysed. RESULTS:EMMPRIN was detected in cancerous tissues of 53 patients with seminoma, but not normal testes. Thirty- five patients showed weakly to moderately positive and 18 patients intensely positive expression. Moreover, positive EMMPRIN staining correlated significantly with various clinicopathological factors (increased TNM stage and higher histological differentiation type) as well as decreased tumour-specific survival (log-rank, p=0.02). In particular, EMMPRIN expression was an independent prognosticator as shown by Cox regression analysis (p<0.001). CONCLUSION:EMMPRIN expression in a primary tumour predicts an unfavourable prognosis in humanseminoma, suggesting its crucial role in the progression of this tumour.
Authors: S Zucker; M Hymowitz; E E Rollo; R Mann; C E Conner; J Cao; H D Foda; D C Tompkins; B P Toole Journal: Am J Pathol Date: 2001-06 Impact factor: 4.307
Authors: Marc Ladanyi; Cristina R Antonescu; Marija Drobnjak; Ann Baren; Man Yee Lui; David W Golde; Carlos Cordon-Cardo Journal: Am J Pathol Date: 2002-04 Impact factor: 4.307
Authors: Lavanya H Palavalli; Todd D Prickett; John R Wunderlich; Xiaomu Wei; Allison S Burrell; Patricia Porter-Gill; Sean Davis; Chenwei Wang; Julia C Cronin; Neena S Agrawal; Jimmy C Lin; Wendy Westbroek; Shelley Hoogstraten-Miller; Alfredo A Molinolo; Patricia Fetsch; Armando C Filie; Michael P O'Connell; Carolyn E Banister; Jason D Howard; Phillip Buckhaults; Ashani T Weeraratna; Lawrence C Brody; Steven A Rosenberg; Yardena Samuels Journal: Nat Genet Date: 2009-03-29 Impact factor: 38.330
Authors: Luís Silva Monteiro; Maria Leonor Delgado; Sara Ricardo; Fernanda Garcez; Barbas do Amaral; José Júlio Pacheco; Carlos Lopes; Hassan Bousbaa Journal: Biomed Res Int Date: 2014-05-21 Impact factor: 3.411
Authors: Cory D Bovenzi; James Hamilton; Patrick Tassone; Jennifer Johnson; David M Cognetti; Adam Luginbuhl; William M Keane; Tingting Zhan; Madalina Tuluc; Voichita Bar-Ad; Ubaldo Martinez-Outschoorn; Joseph M Curry Journal: Biomed Res Int Date: 2015-12-08 Impact factor: 3.411